NCT06801054View on ClinicalTrials.gov

Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Acute Ischemic Stroke

Interventions

DRUG

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

All patients will receive a second dose of tenecteplase.

Trial Locations (1)

77030

Memorial Hermann Hospital, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Grotta Stroke Research Foundation

UNKNOWN

collaborator

Memorial Hermann Hospital Mobile Stroke Unit

UNKNOWN

collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Hermann Health System

OTHER

NCT06801054 - Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose | Biotech Hunter | Biotech Hunter